Now Enrolling Learn More Now Enrolling Learn More Now Enrolling Learn More Latest News Mar 25, 2021 Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors View Press Release Mar 24, 2021 Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress View Press Release Mar 22, 2021 Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
